FDA Investigator Thomas P Hansen

Thomas P Hansen has conducted inspections on 240 sites in 2 countries as of 28 Aug 2014. See below for a list of the FDA enforcement documents resulting from those inspections.

Investigator Details

Number of Inspected Sites:
240
Last Inspection Date:
28 Aug 2014
Investigator Role:
FDA Investigator
Redica ID:
100000665
Countries of Inspections:
United States of America, Canada
FDA Investigators that have inspected at least one site in common with Thomas P Hansen:
Alia Legaux, Alice S Tsao, Althea A Williams, Amy Wyan Mai, Andrew B Paglia, DPM, Andrew Paglia, DPM, Arthur S Williams, Jr, Benton M Ketron, Bernardica T Sculac Stern, Brandy N Lepage, Byungja E Marciante, Christopher S Fields, Ct Viswanathan, PhD, David A Carlson, Dorothy W Lee, Dr. Robert C Horan, MD, Eileen J Bannerman, Erica B Raphael, Evelyn Taha, Farwa Z Razvi, George C Amedro, Gifford Whitehurst, Jr, Gregson A Joseph, Iram R Hassan, PhD, Irina Gaberman, Jacqueline S Warner, James A Liubicich, James D Bridges, Jane C Chen, Joanne M Schlossin, John Dan, Jonathan D Green, Jorge C Rios, MD, Joseph J Vannelli, Joseph Maselli, Joy P Matthias, Karen L Kosar, Kent C Hermann, Kerun Hardeo, Kevin A Gonzalez, Kim M Downing, L Gnnmassimia Massimilla, PharmD, Lawrence W Farina, Leena Thomas, Lisa Mathew, LTJG Matthew R Palo, Matthew A Spataro, Matthew D Schnittker, Michael A Charles, Michael Serrano, Michael W Burd, Mindy M Chou, Nancy A Saxenian Emmons, Nancy M Espinal, Neil J Bonzagni, PhD MPH, Nicole M Bell, Omadevi Somai, Investigator, Perry T Nichols, Peter Abel, Peter R Caparelli, Richard K Glabach, Robert C Steyert, Ronald Ifraimov, Ruth A Williams, Samson O Oluseye, Samuel Eskenazi, Samuel T Walker, Sarah A Meehan, Shreya Shah, Sonia E Ortiz, Sony Mathews, Stephanie T Durso, Sunita Vij, Syeda N Mahazabin, Tara K Carmody, Tara K Normandin, Uduak M Inokon, Valerie Jgrecek Trinh, Xikui Chen (nmi), PhD

Thomas P Hansen's Documents

Publish Date Document Type Title
February, 2012 FDA 483 Biomedical Research Alliance of New York IRB - Form 483, 2012-02-14
April, 2002 FDA 483 Response Dr. Ronald G. Crystal - Form 483R, 2002-05-02
March, 2002 FDA 483 Response Columbia University Medical Center IRB - Form 483R, 2002-10-18
June, 2013 EIR Rogerio Lobo - EIR, 2013-06-25
March, 2001 FDA 483 Scioptic International - Form 483, 2001-03-27
January, 2000 FDA 483 Long Island Ophthalmic Surgery - Form 483, 2000-01-28
December, 2004 FDA 483 Medical Office of Matthew J. Guy, M.D. - Form 483, 2004-12-08
January, 2000 EIR Dr. Richard T. Sturm - EIR, 2000-01-28
June, 2001 FDA 483 New York University Medical Center - Form 483, 2001-06-22
March, 2002 FDA 483 NYU Langone Health Institutional Review Board - Form 483, 2002-03-15
February, 2005 FDA 483 Dr.Gary K. Zammit - Form 483, 2005-02-09
January, 2003 EIR Columbia Univ/Clmba Prsbytrn - EIR, 2003-01-30
April, 2014 FDA 483 Dr. John P. Bilezikian - Form 483, 2014-04-14
February, 2012 EIR Biomedical Research Alliance of New York IRB - EIR, 2012-02-14
March, 2002 EIR Columbia University Medical Center IRB - EIR, 2002-03-15
July, 2001 FDA 483 Response American Health Foundation - Form 483R, 2001-08-15
December, 2004 FDA 483 Response Matthew J. Guy, M.D. - Form 483R, 2004-12-30
February, 2001 FDA 483 Columbia Presbyterian Medical Center - Form 483, 2001-02-09
October, 2000 FDA 483 Dr. Christine Eng - Form 483, 2000-10-12
July, 2001 EIR American Health Foundation - EIR, 2001-07-20
October, 2000 EIR Dr. Christine Eng - EIR, 2000-10-12
June, 2013 FDA 483 Ralf C. Zimmermann - Form 483, 2013-06-25
April, 2001 FDA 483 Dr. Michelle P. Warren - Form 483, 2001-04-09
March, 2004 EIR Dr.Evan Roy Berger - EIR, 2004-03-31
April, 2002 EIR Dr. Ronald G. Crystal - EIR, 2002-04-24
August, 2005 EIR Giardina, Patricia J. MD - EIR, 2005-08-10
November, 2002 EIR Dr. Eric D. Donnenfeld - EIR, 2002-11-08
August, 2001 FDA 483 BETH ISRAEL MEDICAL CENTER - Form 483, 2001-08-16
March, 2002 FDA 483 Columbia University Medical Center IRB - Form 483, 2002-03-15
February, 2001 EIR Dr. Robyn J. Barst - EIR, 2001-02-09
March, 2002 FDA 483 Response NYU Langone Health Institutional Review Board - Form 483R, 2002-05-03
March, 2000 EIR Sankyo U.S.A. Development( Div. of Sankyo Pharma, Inc.) - EIR, 2000-03-30
January, 2014 EIR Mount Sinai School of Medicine IRB #5 - Board D - EIR, 2014-01-31
June, 2013 FDA 483 Response Ralf C. Zimmermann - Form 483R, 2013-07-11
August, 2000 EIR Dr. Richard J. Oringer - EIR, 2000-08-14
June, 2013 FDA 483 Rogerio Lobo - Form 483, 2013-06-25
January, 2003 FDA 483 Columbia Univ/Clmba Prsbytrn - Form 483, 2003-01-30
March, 2002 EIR NYU Langone Health Institutional Review Board - EIR, 2002-03-15
April, 2001 EIR Dr. Michelle P. Warren - EIR, 2001-04-09
June, 2001 EIR Dr. Michael L. Gruber - EIR, 2001-06-22
March, 2001 EIR Pamela U. Freda - EIR, 2001-08-31
December, 2004 EIR Matthew J. Guy, M.D. - EIR, 2004-12-08
August, 2001 EIR Bradley S. Galer , M.D. - EIR, 2001-08-16
August, 2001 EIR Population Council (The) - EIR, 2001-08-31
July, 2001 FDA 483 American Health Foundation - Form 483, 2001-07-20
March, 2002 FDA 483 Forest Research Institute Inc - Form 483, 2002-03-28
August, 2003 FDA 483 Mount Sinai School of Medicine - Form 483, 2003-08-20
February, 2005 FDA 483 Response Dr.Gary K. Zammit - Form 483R, 2005-02-21
March, 2001 FDA 483 Pamela U. Freda - Form 483, 2001-03-09
March, 2001 EIR Scioptic International - EIR, 2001-03-27
April, 2002 FDA 483 New York Hospital Cornell - Form 483, 2002-04-24

Experience Redica Systems’ NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more